Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012CB517805 | Other Grant/Funding Number | National Basic Research Program of China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Bariatric surgery is generally recommended for obese people with a body mass index (BMI) of at least 40kg/m2, and for people with BMI 35 kg/m2 and serious coexisting medical conditions such as diabetes. A variety of studies showed that it cause significant weight loss, recovery from diabetes and improvement in cardiovascular risk factors, such as blood pressure. The recent guidelines suggest that patients with a BMI of more than 30 kg/m2 with co morbidities is a candidate for bariatric surgery. However, the patients with diabetes in Chinese has lower BMI than that in west country. Therefore, this research is designed to observe whether bariatric surgery reduce blood pressure in patients with diabetes and relatively lower BMI.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of hypertension medication prescription | Reduction of hypertension medication prescription related to the baseline hypertension treatment at 12 months after surgery. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Reduction of hypertension medication prescription | Reduction of hypertension medication prescription compared to the baseline hypertension treatment at 1, 3 and 6 months. | 1 month to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in systolic blood pressure | 1 to 12 months | |
| Change from baseline in diastolic blood pressure | 1 to 12 months | |
| Change from baseline in body weight |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with obesity and diabetes
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hongbo He, MD. | Contact | 86-23-69757880 | cqhehongbo@gmail.com | |
| Zhiming Zhu, MD., PhD. | Contact | 86-23-68767881 | zhuzm@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Third Military Medical University | Recruiting | Chongqing | Chongqing Municipality | 400042 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33197293 | Derived | Sun F, Zhou X, Li Q, Li Y, Zhang H, Yan Z, He H, Zhao Z, Ke Z, Gao Y, Li F, Tong W, Zhu Z. Achieving blood pressure targets and antihypertensive effects through metabolic surgery in type 2 diabetes patients with hypertension. Diabetes Metab Res Rev. 2021 May;37(4):e3422. doi: 10.1002/dmrr.3422. Epub 2020 Nov 30. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D003920 | Diabetes Mellitus |
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood sample
| 1 to 12 months |
| Change from baseline in body mass index | 1 to 12 months |
| Change from baseline in waist circumference | 1 to 12 months |
| Change from baseline in body fat distribution | 1 to 12 months |
| Change from baseline in fasting plasma glucose | 1 to 12 months |
| Change from baseline in fasting plasma insulin | 1 to 12 months |
| Change from baseline in HbA1c | 3 to 12 months |
| Change from baseline in total cholesterol | 1 to 12 months |
| Change from baseline in LDL-cholesterol | 1 to 12 months |
| Change from baseline in HDL-cholesterol | 1 to 12 months |
| Change from baseline in triglycerides | 1 to 12 months |
| Change from baseline in artery vasodilative function | Endothelium-dependent nitroglycerin(NTG)-induced dilatation and flow-mediated dilatation (FMD) by non-invasive high-resolution ultrasound. | 1 to 12 months |
| Change from baseline in serum amino acids level | 1 to 12 months |
| Change from baseline in sense of taste | 1 to 12 months |
| Change from baseline in hepatic enzymes | 1 to 12 months |
| Change from baseline in serum creatine | 1 to 12 months |
| Change from baseline in serum electrolyte | 1 to 12 months |
| Change from baseline in complete blood count | 1 to 12 months |
| Adverse events | 1 to 12 months |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |